Nick DiFranco, MEM
Senior Marketing Manager, Pharmaceuticals
Gattefosse
What are the current trends in patient centric drug delivery in the pharmaceutical industry, and how are these trends reshaping clinical trial design, formulation strategies, and patient adherence?
Patient-centricity is fundamentally reshaping formulation strategies by demanding dosage forms that accommodate specific demographic needs rather than relying on a traditional, one-size-fits-all approach. Lipid excipients enable key innovations that improve the patient experience, including injectable-to-oral switches, pediatric/geriatric-friendly formats, and improved patient experience for topical formulations.
The “holy grail” of patient-centricity remains the transition of injectable therapies to oral dosage forms, a move that drastically improves patient compliance and overall quality of life. A prime example of this injectable-to-oral switch is the evolution of testosterone replacement therapy (TRT). Testosterone was historically relegated to painful intramuscular injections or topical gels due to extensive hepatic first-pass metabolism and poor aqueous solubility. However, several oral capsule formulations for TRT have been launched in recent years. This breakthrough is driven by lipid-based formulations, which enhance drug solubilization within the gastrointestinal tract and promote lymphatic transport to bypass liver degradation. By leveraging lipid-based delivery to access benefits such as tight junction modulation and lymphatic uptake, formulators can overcome gastrointestinal hurdles and enable oral delivery of other promising molecules, including peptides and GLP-1 agonists.
For pediatric and geriatric populations, we are seeing growing interest in multiparticulate formulations and oral liquids. These flexible delivery systems allow for precise dose titration and overcome common swallowing difficulties, directly improving both patient adherence and commercial viability. Lipid excipients play a key role in enhancing multiparticulate performance, offering taste-masking and extended-release performance (e.g., Compritol® 888 ATO, Precirol® ATO 5) and bioavailability enhancement (e.g., Gelucire® 50/13).
Innovation within the topical and transdermal space is also centered on improving the patient experience. Formulators are increasingly prioritizing sensory characteristics — focusing on improved aesthetics, elegant textures, and novel delivery formats like foams — to ensure treatments seamlessly integrate into patients’ daily routines. In the United States, this drive for highly tailored therapeutic solutions is further evidenced by the robust growth of compounding pharmacies, which provide individualized medicine options.
What are the main regulatory considerations and hurdles when designing patient centric drug delivery systems, and how can sponsors engage effectively with agencies to align on patient centricity driven endpoints and device drug combinations?
Lifecycle management and reformulation projects offer a win-win for pharmaceutical companies and patients — enabling more effective, convenient, and tailored medicines. However, formulators must strike a balance between introducing new functionality and ensuring regulatory compliance.
While novel excipients and formulation approaches offer technical appeal, they can significantly impact time to market due to increased regulatory scrutiny. This creates an “innovation paradox” where patients desire improved options, but regulators demand proven safety. Lipid excipients solve this by offering innovative functionality, such as food-effect mitigation, while utilizing materials with established GRAS status and global monographs. This minimizes CMC risk while maximizing patient benefit through improved dosing regimens.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from American Pharmaceutical Review delivered to your inbox!
Sign up now!